TXNIP-IN-1 is TXNIP-TRX (thioredoxin-interacting protein- thioredoxin) complex inhibitor extracted from patent US20200085800A1, Compound 1. TXNIP-IN-1 can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease[1].
TXNIP-IN-1 bocks high glucose (HG induced) TXNIP-TRX complex formation[1].TXNIP-IN-1 (1.25-5 μM) reduces HG-induced expression of TNF in monocytes[1].TXNIP-IN-1 (1.25-5 μM; 72 hours) inhibits TXNIP mRNA expression in THP1 cells[1].TXNIP-IN-1 (0.3-10 μM; 72 hours) inhibits TXNIP mRNA expression in murine RAW macrophages[1].TXNIP-IN-1 (5-20 μM; 72 hours) decreases TXNIP but not TNF-alpha mRNA levels in MIN6 cells[1].TXNIP-IN-1 (0.62-5 μM; 72 hours) affects TXNIP and TNF-alpha mRNA expression in human pancreas 1.1B4 beta cells[1].TXNIP-IN-1 (5 μM; 16-72 hours) inhibits c-TRX interaction in THP1 cells cultured in 25mM glucose[1].TXNIP-IN-1 targets TXNIP mRNA in human pancreatic islets[1].
[1]. Rama Natarajan, et al. Txnip-trx complex inhibitors and methods of using the same. US20200085800A1.